G W Elmer

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
    G W Elmer
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle 98195, USA
    Aliment Pharmacol Ther 13:1663-8. 1999
  2. ncbi Probiotics: "living drugs"
    G W Elmer
    Medicinal Chemistry, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA
    Am J Health Syst Pharm 58:1101-9. 2001
  3. ncbi Biotherapeutic agents in the treatment of infectious diarrhea
    G W Elmer
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA
    Gastroenterol Clin North Am 30:837-54. 2001
  4. ncbi The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii
    C M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washoington, Seattle, WA USA
    Clin Infect Dis 31:1012-7. 2000
  5. ncbi Possible interaction between warfarin and Lycium barbarum L
    A Y Lam
    Department of Pharmacy, University of Washington, Seattle 98104 3031, USA
    Ann Pharmacother 35:1199-201. 2001

Detail Information

Publications5

  1. ncbi Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients
    G W Elmer
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle 98195, USA
    Aliment Pharmacol Ther 13:1663-8. 1999
    ..The present study reports the stool concentrations of Saccharomyces boulardii in a patient population with Clostridium difficile disease (CDD) and correlates stool concentrations with efficacy...
  2. ncbi Probiotics: "living drugs"
    G W Elmer
    Medicinal Chemistry, School of Pharmacy, University of Washington, Box 357610, Seattle, WA 98195, USA
    Am J Health Syst Pharm 58:1101-9. 2001
    ..Effective use of probiotics could decrease patients' exposure to antimicrobials. Additional controlled studies are needed to clearly define the safety and efficacy of these agents...
  3. ncbi Biotherapeutic agents in the treatment of infectious diarrhea
    G W Elmer
    Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington, USA
    Gastroenterol Clin North Am 30:837-54. 2001
    ..However, for many biotherapeutic agents, well-done, placebo-controlled trials still are lacking, and not all types of infectious diarrhea respond to these agents. Continued research in this innovative therapeutic area is warranted...
  4. ncbi The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii
    C M Surawicz
    Division of Gastroenterology, Department of Medicine, University of Washoington, Seattle, WA USA
    Clin Infect Dis 31:1012-7. 2000
    ..Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high-dose vancomycin or to longer courses of low-dose vancomycin when either is combined with S. boulardii...
  5. ncbi Possible interaction between warfarin and Lycium barbarum L
    A Y Lam
    Department of Pharmacy, University of Washington, Seattle 98104 3031, USA
    Ann Pharmacother 35:1199-201. 2001
    ..Additionally, to determine the effect of the tea on CYP2C9, the isoenzyme responsible for the metabolism of S-warfarin...